Stockreport

Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

Citius Pharmaceuticals, Inc.  (CTXR) 
NASDAQ:AMEX Investor Relations: ir.citiuspharma.com
PDF CRANFORD, N.J., Feb. 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjun [Read more]